Roche's HIV monitor may benefit more patients
This article was originally published in Clinica
Executive Summary
Roche Diagnostics has gained FDA clearance to market in the US a new version of its HIV-1 monitor assay, which the firm claims is the most sensitive on the market and which may benefit a broader patient population.